Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Dirk-Jan A. R. Moes"'
Autor:
Anna E. C. Stoelinga, Maarten E. Tushuizen, Wilbert B. van den Hout, Mar D. M. Rodriguez Girondo, Elsemieke S. de Vries, Amar D. Levens, Dirk-Jan A. R. Moes, Tom J. G. Gevers, Suzanne van der Meer, Hans T. Brouwer, Hendrik J. M. de Jonge, Ynte S. de Boer, Ulrich H. W. Beuers, Adriaan J. van der Meer, Aad P. van den Berg, Maureen M. J. Guichelaar, Joost P. H. Drenth, Bart van Hoek, on behalf of the Dutch Autoimmune Hepatitis Group
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Autoimmune hepatitis (AIH) is a rare, chronic inflammatory disease of the liver. The treatment goal is reaching complete biochemical response (CR), defined as the normalisation of aspartate and alanine aminotransferases and immuno
Externí odkaz:
https://doaj.org/article/e9871b3711e44943a5adbb67b77352b2
Autor:
Stefanie D. Krens, Nielka P. van Erp, Stefanie L. Groenland, Dirk Jan A. R. Moes, Sasja F. Mulder, Ingrid M. E. Desar, Tom van der Hulle, Neeltje Steeghs, Carla M. L. van Herpen
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Aim In the registration trial, cabozantinib exposure ≥ 750 ng/mL correlated to improved tumor size reduction, response rate and progression free survival (PFS) in patients with metastatic renal cell cancer (mRCC). Because patients in routi
Externí odkaz:
https://doaj.org/article/f27b5243be1f49888ffdb384331fa067
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-14 (2022)
Abstract Quantitative characterization of evolving tumor resistance under targeted treatment could help identify novel treatment schedules, which may improve the outcome of anti-cancer treatment. In this study, a mathematical model which considers va
Externí odkaz:
https://doaj.org/article/1ee39881ae464dc7bfd80c8292074cc0
Autor:
M. Y. Eileen C. van der Stoep, Lisa V. E. Oostenbrink, Robbert G. M. Bredius, Dirk Jan A. R. Moes, Henk-Jan Guchelaar, Juliette Zwaveling, Arjan C. Lankester
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established curative treatment that has significantly improved clinical outcome of pediatric patients with malignant and non-malignant disorders. This is partly because of the use of saf
Externí odkaz:
https://doaj.org/article/aab977d8e9ee488c9aa14ced7a54e661
Autor:
Aliede E. in ’t Veld, Manon A. A. Jansen, Bertine W. Huisman, Mascha Schoonakker, Marieke L. de Kam, Dirk Jan A. R. Moes, Mariëtte I. E. van Poelgeest, Jacobus Burggraaf, Matthijs Moerland
Publikováno v:
Pharmaceutics, Vol 14, Iss 9, p 1958 (2022)
Therapeutic drug monitoring (TDM) of calcineurin inhibitors (i.e., tacrolimus and cyclosporin A) is standard of care after solid organ transplantation. Although the incidence of acute rejection has strongly decreased, there are still many patients wh
Externí odkaz:
https://doaj.org/article/7f17bd0e146741d48b5ea7e1ead8b76b
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-2 (2022)
Externí odkaz:
https://doaj.org/article/fa287f3e6e3c4d4f86bf8631be5970fa
Autor:
Etienne Chatelut, Jeroen J. M. A. Hendrikx, Jennifer Martin, Joseph Ciccolini, Dirk Jan A. R. Moes
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 2, Pp n/a-n/a (2021)
Abstract Monoclonal antibodies (Mabs) have become key drugs in cancer treatment, either as targeted therapies or more recently as immune checkpoint inhibitors (ICIs). The fact that only some patients benefit from these drugs poses the usual question
Externí odkaz:
https://doaj.org/article/de932d7a0fe14f119b38e5a85bccf4de
Autor:
Federica R. Achini-Gutzwiller, Cornelia M. Jol-van der Zijde, Anja M. Jansen-Hoogendijk, Arjan C. Lankester, Robbert G. M. Bredius, Maarten J. D. van Tol, Dirk Jan A. R. Moes, Marco W. Schilham
Publikováno v:
Therapeutic Drug Monitoring. 45:79-86
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Tacrolimus is metabolized by CYP3A4 and CYP3A5 enzymes. Patients expressing CYP3A5 (in Caucasian patients about 15% of the population but more frequent in African Americans and Asians) have a dose requirement that is around 50% higher than non-expres
Externí odkaz:
https://doaj.org/article/4e70c9272dca40afaf1f5dcab43680fd
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 15, p 8031 (2021)
In alpha-1-antitrypsin deficiency (AATD), neutrophil serine proteases such as elastase and proteinase 3 (PR3) are insufficiently inhibited. A previous study in AATD patients showed a higher plasma level of the specific PR3-generated fibrinogen-derive
Externí odkaz:
https://doaj.org/article/c2a8e01283ba4fbbb33423a6db91087e